| |
Join us on Dec. 7 for a webinar exploring compendia surveillance and Eurofins BioPharma Product Testing’s processes in maintaining compliance. Register now. 
|
|
Today’s Big NewsNov 6, 2023 |
|
January 9-10, 2024 | San Francisco, CA
January 16-18, 2024 | Virtual
Scoring for Patients: How Reducing Risk in 2023 Will Change the Fame for Drug Discovery and Development
Register today and Save $450!
 |
|
| By Fraiser Kansteiner Last week, the U.K.'s National Institute for Health and Care Excellence unveiled draft guidance that acknowledged the effectiveness of Vertex’s cystic fibrosis drugs Trikafta, Symkevi and Orkambi. But the agency stopped short of labeling the medicines cost effective. |
|
|
|
By Andrea Park Attorneys general representing half of the U.S. and Washington, D.C., are calling on the FDA to step up its efforts to eliminate racial bias from pulse oximetry technology. |
By Max Bayer Pfizer has handed off an AAV capsid aimed at a rare neurological disease target to AstraZeneca’s rare disease arm Alexion as part of a larger, previously announced bundle deal. |
By Eric Sagonowsky Astellas is counting on Izervay to deliver gains in a heated GA market clash against rival Apellis. Now, 2-year data show the drug's effects increase over time. |
By Annalee Armstrong Another day, another antibody-drug conjugate deal. This time it’s Bristol Myers Squibb snapping up Orum Therapeutics’ phase 1 blood cancer med for $100 million upfront. |
By Conor Hale BD is building on its goal of providing patients with a “one-stick hospital stay,” with a new FDA clearance for painless blood collection hardware that works through already placed IV lines. |
By Max Bayer BioNTech is spending more of its COVID cash, betting over $1 billion on a licensing deal for a phase 2 bispecific antibody, just days after closing the acquisition of a lipid nanoparticle startup. |
By Kevin Dunleavy Krystal Biotech's launch of Vyjuvek, the world's first topical gene therapy, has been so promising that analysts with Evercore ISI increased their 2024 sales projection to $273 million. The drug launched after an FDA approval in May 2023. |
By Andrea Park People suffering from chronic insomnia now have a new, drug-free option to treat the condition in the U.S. |
By Helen Floersh Academics and industry folks from around the cancer world convened in sunny San Diego Nov. 1-5 at the Society for Immunotherapy of Cancer’s annual conference. Here are a few preclinical highlights. |
By Zoey Becker The company plans to expand its Auvelity sales force from 162 to 260 reps by next quarter in an effort to reach some 18,000 new prescribers. |
By James Waldron MoonLake Immunotherapeutics has maintained its position as a key player in the race to get an IL-17 inhibitor to market for inflammatory skin conditions courtesy of another successful phase 2 readout. |
By Conor Hale The effort—dubbed TRICORDER, inspired by the Star Trek handheld health scanner, and described as a large-scale deployment—is being funded by the U.K.’s National Institute for Health and Care Research. |
Fierce podcasts Don’t miss an episode |
| While the new Alzheimer’s disease medicine Leqembi has generated lots of buzz since its debut this year, one research team is investigating whether the medicine holds promise in preventing disease progression before any Alzheimer’s symptoms are evident. In this week's episode of "The Top Line," Fierce Pharma’s Eric Sagonowsky talks with the study lead, Reisa Sperling, M.D., to learn more. |
|
|---|
|
|
Whitepaper A critical area to consider in selecting a CDMO is their ability to successfully complete technology transfers, which involves an intricate set of activities and disciplines that, if done incorrectly, could result in delays and failures that impact the overall success of your end product. Recognizing what it takes to complete this process effectively and efficiently is crucial to selecting the best partner for your project and product needs. This white paper delivers an analysis of critical success factors for effective technology transfer. Sponsored by: Lonza |
Whitepaper Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your bioprocessing workflows. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
Whitepaper Download our whitepaper to learn about plasmid DNA design considerations for cell and gene therapy applications. Sponsored by: Aldevron, a GMP manufacturing CDMO of DNA, RNA, and Proteins |
Whitepaper This paper explores AI’s potential impact on healthcare and on Medical Affairs (MA) more specifically. It also outlines what MA teams can do now to proactively leverage AI to improve service to their stakeholders. Presented by Blue Matter, strategic consultants in the life sciences |
eBook Emulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
Whitepaper Accelerate drug discovery with high-performance computing (HPC) powered by the cloud Sponsored By: AWS, NVIDIA, and Rescale |
| Edison Ballroom, New York City |
|
|
| |
|
